{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:15:26Z","timestamp":1788185726718,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00432-023-04766-3","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T07:02:52Z","timestamp":1681714972000},"page":"8243-8253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-6966","authenticated-orcid":false,"given":"Ahmet","family":"Bilici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Karaagac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin Goktas","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"Eraslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Ali","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birol","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Sezgin","family":"Goksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Paydas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"Akgul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeyye","family":"Derin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakup","family":"Ergun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yekeduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Tataroglu","family":"Ozyukseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atike Gokcen","family":"Demiray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Gulsum","family":"Guc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Menekse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva Yesil","family":"Cinkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Gumusay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Sakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Ozkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Besiroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olcun Umit","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokman","family":"Koral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleyman","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"Sakalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"Bahceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ozveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulug Mutlu","family":"Gunaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Metin","family":"Seker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli","family":"Sunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Turhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"4766_CR1","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.2147\/CMAR.S323499","volume":"13","author":"B Alshamsan","year":"2021","unstructured":"Alshamsan B, Badran A, Alshibany A et al (2021) Real-world outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma. Cancer Manag Res 13:6755\u20136766. https:\/\/doi.org\/10.2147\/CMAR.S323499","journal-title":"Cancer Manag Res"},{"key":"4766_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5505\/aot.2022.37108","volume":"55","author":"MB Aykan","year":"2022","unstructured":"Aykan MB, Keskin GS, \u00d6rnek E et al (2022) Efficacy of pazopanib in patients with pretreated advanced stage soft tissue sarcomas. Acta Oncologica Turcica 55:229\u2013236. https:\/\/doi.org\/10.5505\/aot.2022.37108","journal-title":"Acta Oncologica Turcica"},{"issue":"3","key":"4766_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4103\/ijc.IJC_314_19","volume":"58","author":"J Bajpai","year":"2021","unstructured":"Bajpai J, Mullapally SK, Kapoor A, Ghosh J, Rekhi B (2021) Pazopanib in metastatic soft tissue sarcomas: testing the waters in developing world. Indian J Cancer 58(3):365\u2013370. https:\/\/doi.org\/10.4103\/ijc.IJC_314_19","journal-title":"Indian J Cancer"},{"issue":"1","key":"4766_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.6004\/jadpro.2022.13.1.6","volume":"13","author":"KL Byar","year":"2022","unstructured":"Byar KL, Fredericks T (2022) Uterine leiomyosarcoma. J Adv Pract Oncol 13(1):70\u201376. https:\/\/doi.org\/10.6004\/jadpro.2022.13.1.6","journal-title":"J Adv Pract Oncol"},{"issue":"32","key":"4766_CR5","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2217\/fon-2022-0348","volume":"18","author":"C Carroll","year":"2022","unstructured":"Carroll C, Patel N, Gunsoy NB, Stirnadel-Farrant HA, Pokras S (2022) Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). Future Oncol 18(32):3651\u20133665. https:\/\/doi.org\/10.2217\/fon-2022-0348","journal-title":"Future Oncol"},{"issue":"12","key":"4766_CR6","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1080\/0284186X.2017.1332779","volume":"56","author":"H Gelderblom","year":"2017","unstructured":"Gelderblom H, Judson IR, Benson C et al (2017) Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. Acta Oncol 56(12):1769\u20131775. https:\/\/doi.org\/10.1080\/0284186X.2017.1332779","journal-title":"Acta Oncol"},{"issue":"11","key":"4766_CR7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP et al (2021) Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(11):1348\u20131365. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006","journal-title":"Ann Oncol"},{"key":"4766_CR8","doi-asserted-by":"publisher","first-page":"100275","DOI":"10.1016\/j.ctarc.2020.100275","volume":"26","author":"NA Halim","year":"2021","unstructured":"Halim NA, Sayed RE, Alameh IA et al (2021) Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: a real-life tertiary-center experience in the MENA region. Cancer Treat Res Commun 26:100275. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100275","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"4766_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/ajco.13029","volume":"14","author":"PW Huang","year":"2018","unstructured":"Huang PW, Chou WC, Shen WC et al (2018) Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: a multicenter study in the Asian population. Asia Pac J Clin Oncol 14(4):353\u2013360. https:\/\/doi.org\/10.1111\/ajco.13029","journal-title":"Asia Pac J Clin Oncol"},{"key":"4766_CR10","doi-asserted-by":"publisher","first-page":"924648","DOI":"10.3389\/fphar.2022.924648","volume":"13","author":"CJ Jonker","year":"2022","unstructured":"Jonker CJ, Bakker E, Kurz X, Plueschke K (2022) Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol 13:924648. https:\/\/doi.org\/10.3389\/fphar.2022.924648","journal-title":"Front Pharmacol"},{"issue":"7","key":"4766_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1177\/1078155220904138","volume":"26","author":"M Karaa\u011fa\u00e7","year":"2020","unstructured":"Karaa\u011fa\u00e7 M, Sezgin Y, Ery\u0131lmaz MK, Araz M, Kaplan MA, Arta\u00e7 M (2020) The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: a retrospective cross-sectional study of a Turkish cohort. J Oncol Pharm Pract 26(7):1657\u20131666. https:\/\/doi.org\/10.1177\/1078155220904138","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"4766_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdt586","volume":"25","author":"B Kasper","year":"2014","unstructured":"Kasper B, Sleijfer S, Liti\u00e8re S et al (2014) Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European organisation for research and treatment of cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 25(3):719\u2013724. https:\/\/doi.org\/10.1093\/annonc\/mdt586","journal-title":"Ann Oncol"},{"issue":"3","key":"4766_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/1078155220924075","volume":"27","author":"S Koca","year":"2021","unstructured":"Koca S, Be\u015firo\u011flu M, \u00d6z\u00e7elik M et al (2021) Pazopanib for metastatic soft-tissue sarcoma: a multicenter retrospective study. J Oncol Pharm Pract 27(3):541\u2013546. https:\/\/doi.org\/10.1177\/1078155220924075","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"4766_CR14","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-12-2934","volume":"19","author":"RL Korn","year":"2013","unstructured":"Korn RL, Crowley JJ (2013) Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res 19(10):2607\u20132612. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2934","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4766_CR15","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar R, Knick VB, Rudolph SK et al (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7):2012\u20132021. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0193","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"4766_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/cncr.29961","volume":"122","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Matsumine A, Kawai A et al (2016) The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese musculoskeletal oncology group (JMOG) study. Cancer 122(9):1408\u20131416. https:\/\/doi.org\/10.1002\/cncr.29961","journal-title":"Cancer"},{"issue":"4","key":"4766_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11523-020-00731-z","volume":"15","author":"CR Oh","year":"2020","unstructured":"Oh CR, Hong JY, Kim JH et al (2020) Real-world outcomes of pazopanib treatment in Korean patients with advanced soft tissue sarcoma: a multicenter retrospective cohort study. Target Oncol 15(4):485\u2013493. https:\/\/doi.org\/10.1007\/s11523-020-00731-z","journal-title":"Target Oncol"},{"issue":"1","key":"4766_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CEJ.0000000000000768","volume":"32","author":"M Pizzato","year":"2023","unstructured":"Pizzato M, Collatuzzo G, Santucci C et al (2023) Mortality patterns of soft-tissue sarcomas worldwide up to 2018, with predictions for 2025. Eur J Cancer Prev 32(1):71\u201380. https:\/\/doi.org\/10.1097\/CEJ.0000000000000768","journal-title":"Eur J Cancer Prev"},{"issue":"32","key":"4766_CR19","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.2217\/fon-2022-0477","volume":"18","author":"S Pokras","year":"2022","unstructured":"Pokras S, Tseng WY, Espirito JL, Beeks A, Culver K, Nadler E (2022) Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network. Future Oncol 18(32):3637\u20133650. https:\/\/doi.org\/10.2217\/fon-2022-0477","journal-title":"Future Oncol"},{"issue":"1","key":"4766_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12885-017-3057-3","volume":"17","author":"I Ray-Coquard","year":"2017","unstructured":"Ray-Coquard I, Collard O, Ducimetiere F et al (2017) Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). BMC Cancer 17(1):111. https:\/\/doi.org\/10.1186\/s12885-017-3057-3","journal-title":"BMC Cancer"},{"issue":"2","key":"4766_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"M Sbaraglia","year":"2021","unstructured":"Sbaraglia M, Bellan E, Dei Tos AP (2021) The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 113(2):70\u201384. https:\/\/doi.org\/10.32074\/1591-951X-213","journal-title":"Pathologica"},{"key":"4766_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"issue":"3","key":"4766_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/medsci7030048","volume":"7","author":"T Seto","year":"2019","unstructured":"Seto T, Song MN, Trieu M et al (2019) Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California. Med Sci (Basel) 7(3):48. https:\/\/doi.org\/10.3390\/medsci7030048","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"4766_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"4766_CR25","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27(19):3126\u20133132. https:\/\/doi.org\/10.1200\/JCO.2008.21.3223","journal-title":"J Clin Oncol"},{"issue":"9829","key":"4766_CR26","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879\u20131886. https:\/\/doi.org\/10.1016\/S0140-6736(12)60651-5","journal-title":"Lancet"},{"key":"4766_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12885-015-1160-x","volume":"15","author":"KH Yoo","year":"2015","unstructured":"Yoo KH, Kim HS, Lee SJ et al (2015) Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer 15:154. https:\/\/doi.org\/10.1186\/s12885-015-1160-x","journal-title":"BMC Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04766-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T20:32:36Z","timestamp":1690489956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04766-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4766"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04766-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}